PURE Bioscience, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
PURE Bioscience, Inc. (PURE) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations of 327.76 thousand shares for the 12-month period ending 2022-07-31, per its 10-K filed 2022-10-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations · last filed 2022-10-28
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2022 was 327.76K shares.
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2020 was 133.33K shares.
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2018 was 113.52K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 12 month |
|---|---|
| 2022-07-31 | 327.76K shares 10-K · filed 2022-10-28 |
| 2020-07-31 | 133.33K shares 10-K · filed 2021-10-28 |
| 2018-07-31 | 113.52K shares 10-K · filed 2019-10-30 |